Literature DB >> 8162936

Preparation of a potential positron emission tomographic radioligand for the dopamine transporter.

L Müller1, C Halldin, C Foged, P Karlsson, H Hall, C G Swahn, P D Suzdak, R Hohlweg, E B Nielsen, L Farde.   

Abstract

NNC 12-0722 (1-[2-(bis(4-fluorophenyl)-methoxy)ethyl]-4-methyl piperazine) is a new selective inhibitor of the dopamine transporter. [11C]NNC 12-0722 was prepared by N-methylation of the desmethyl compound with [11C]methyl iodide. The total radiochemical yield of [11C]NNC 12-0722 was 40%-50% with an overall synthesis time of 30-35 min. The radiochemical purity was higher than 99% and the specific radioactivity about 1500 Ci/mmol (55 GBq/mumol). Autoradiographic examination of [11C]NNC 12-0722 binding on whole hemisphere cryosections from human brain post mortem demonstrated specific binding in the caudate nucleus and putamen. In a positron emission tomographic examination of [11C]NNC 12-0722 in a cynomolgus monkey there was a rapid uptake of radioactivity in the brain. In the striatum, a region with a high density of dopamine transporters, the radioactivity was two times higher than in the cerebellum. These results indicate that [11C]NNC 12-0722 may be a useful radioligand for labelling of the dopamine transporter in man.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162936     DOI: 10.1007/bf00175760

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  19 in total

1.  Autoradiography with saturation experiments of 11C-Ro 15-1788 binding to human brain sections.

Authors:  A Persson; R d'Argy; P G Gillberg; C Halldin; J E Litton; C G Swahn; G Sedvall
Journal:  J Neurosci Methods       Date:  1991-01       Impact factor: 2.390

2.  Neuronal uptake inhibitors, nisoxetine and fluoxetine on rat vascular contractions.

Authors:  M L Cohen; K S Wiley
Journal:  Eur J Pharmacol       Date:  1977-08-01       Impact factor: 4.432

3.  In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography.

Authors:  S M Aquilonius; K Bergström; S A Eckernäs; P Hartvig; K L Leenders; H Lundquist; G Antoni; A Gee; A Rimland; J Uhlin
Journal:  Acta Neurol Scand       Date:  1987-10       Impact factor: 3.209

4.  [3H]GBR 12935 binding in vivo in mouse brain: labelling of a piperazine acceptor site.

Authors:  P H Andersen; J A Jansen; E B Nielsen
Journal:  Eur J Pharmacol       Date:  1987-11-24       Impact factor: 4.432

Review 5.  Dopamine transporter: biochemistry, pharmacology and imaging.

Authors:  M J Kuhar; P M Sanchez-Roa; D F Wong; R F Dannals; D E Grigoriadis; R Lew; M Milberger
Journal:  Eur Neurol       Date:  1990       Impact factor: 1.710

6.  The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.

Authors:  P H Andersen
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

7.  Biodistribution, dosimetry, metabolism and monkey PET studies of [18F]GBR 13119. Imaging the dopamine uptake system in vivo.

Authors:  M R Kilbourn; J E Carey; R A Koeppe; M S Haka; G D Hutchins; P S Sherman; D E Kuhl
Journal:  Int J Rad Appl Instrum B       Date:  1989

8.  Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis.

Authors:  L Farde; L Eriksson; G Blomquist; C Halldin
Journal:  J Cereb Blood Flow Metab       Date:  1989-10       Impact factor: 6.200

9.  The neurotoxic compound N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP4) depletes endogenous norepinephrine and enhances release of [3H]norepinephrine from rat cortical slices.

Authors:  M E Landa; M C Rubio; G Jaim-Etcheverry
Journal:  J Pharmacol Exp Ther       Date:  1984-10       Impact factor: 4.030

10.  Binding of [3H]SCH 39166 to human post mortem brain tissue.

Authors:  H Hall; C Halldin; G Sedvall
Journal:  Pharmacol Toxicol       Date:  1993-03
View more
  1 in total

1.  [11C]NNC 12-0722 or [18F]GBR 13119: just what is "better"?

Authors:  M R Kilbourn
Journal:  Eur J Nucl Med       Date:  1994-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.